These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 19204418)

  • 61. [Nocebo--the antipode to placebo].
    Kaada B
    Nord Med; 1989; 104(6-7):192-8. PubMed ID: 2734096
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Characterization of Pharmacogenetic Information in Food and Drug Administration Drug Labeling and the Table of Pharmacogenetic Associations.
    Cheng CM; So TW; Bubp JL
    Ann Pharmacother; 2021 Oct; 55(10):1185-1194. PubMed ID: 33384014
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Motor and cognitive placebo-/nocebo-responses in Parkinson's disease patients with deep brain stimulation.
    Keitel A; Wojtecki L; Hirschmann J; Hartmann CJ; Ferrea S; Südmeyer M; Schnitzler A
    Behav Brain Res; 2013 Aug; 250():199-205. PubMed ID: 23651878
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacogenetic Predictors of Response.
    Hertz DL; Rae JM
    Adv Exp Med Biol; 2016; 882():191-215. PubMed ID: 26987536
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacogenetic information for patients on drug labels.
    Haga SB; Mills R; Moaddeb J
    Pharmgenomics Pers Med; 2014; 7():297-305. PubMed ID: 25342916
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Pharmacogenetic testing: utility in drug development and in routine clinical practice].
    Jaillon P
    Bull Acad Natl Med; 2006 Jan; 190(1):25-34; discussion 34-6. PubMed ID: 16878444
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Therapeutic Role of Placebo: Evolution of a New Paradigm in Understanding Research and Clinical Practice.
    Manchikanti L; Boswell MV; Kaye AD; Helm Ii S; Hirsch JA
    Pain Physician; 2017 Jul; 20(5):363-386. PubMed ID: 28727700
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Understanding the mechanisms of placebo and nocebo effects.
    Frisaldi E; Shaibani A; Benedetti F
    Swiss Med Wkly; 2020 Aug; 150():w20340. PubMed ID: 32920787
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacogenomics and the Placebo Response.
    Hall KT; Loscalzo J; Kaptchuk T
    ACS Chem Neurosci; 2018 Apr; 9(4):633-635. PubMed ID: 29498823
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Can Positive Framing Reduce Nocebo Side Effects? Current Evidence and Recommendation for Future Research.
    Barnes K; Faasse K; Geers AL; Helfer SG; Sharpe L; Colloca L; Colagiuri B
    Front Pharmacol; 2019; 10():167. PubMed ID: 30894815
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical implications of opioid pharmacogenetics.
    Argoff CE
    Clin J Pain; 2010 Jan; 26 Suppl 10():S16-20. PubMed ID: 20026961
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Placebo and nocebo effects in itch and pain.
    Evers AW; Bartels DJ; van Laarhoven AI
    Handb Exp Pharmacol; 2014; 225():205-14. PubMed ID: 25304534
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacogenetics and personalised medicine: maintain a critical approach.
    Prescrire Int; 2013 Jun; 22(139):161-3. PubMed ID: 23866362
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of acute psychological stress on placebo and nocebo responses in a clinically relevant model of visceroception.
    Roderigo T; Benson S; Schöls M; Hetkamp M; Schedlowski M; Enck P; Elsenbruch S
    Pain; 2017 Aug; 158(8):1489-1498. PubMed ID: 28471874
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS).
    Bothos E; Ntoumou E; Kelaidoni K; Roukas D; Drakoulis N; Papasavva M; Karakostis FA; Moulos P; Karakostis K
    J Transl Med; 2021 Apr; 19(1):151. PubMed ID: 33858454
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Pharmacogenetics in future medical care -- implications for patients and physicians].
    Rogausch A; Brockmöller J; Himmel W
    Gesundheitswesen; 2005 Apr; 67(4):257-63. PubMed ID: 15856385
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Medicine's inconvenient truth: the placebo and nocebo effect.
    Arnold MH; Finniss DG; Kerridge I
    Intern Med J; 2014 Apr; 44(4):398-405. PubMed ID: 24754688
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The potential of pharmacogenetics in the treatment of epilepsy.
    Depondt C
    Eur J Paediatr Neurol; 2006 Mar; 10(2):57-65. PubMed ID: 16531088
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review.
    Häuser W; Bartram C; Bartram-Wunn E; Tölle T
    Clin J Pain; 2012 Jun; 28(5):437-51. PubMed ID: 22336767
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The placebo-nocebo response: controversies and challenges from clinical and research perspective.
    Jakovljevic M
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):333-41. PubMed ID: 24393653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.